ClinicalTrials.gg
TerminatedNCT04575766Updated Aug 9, 2023

A Study of FT-7051 in Men With MCRPC

A Phase 1 interventional study of FT-7051 in Metastatic Castration-resistant Prostate Cancer, sponsored by Novo Nordisk A/S. Terminated at 8 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
2,089th of 3,023
25 · median 48
Started
2020
with 167 others
Phase 1
615 of 3,596
83 open now
Registered
2,614th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 2,089th largest by enrollment of the 3,023 interventional ones that give a count, is one of 168 that started in 2020, is one of 615 in phase 1, and was the 2,614th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy.

The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on/7 days off) in 28-day cycles.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Keywords

  • Metastatic Castration-resistant Prostate Cancer
  • Prostate cancer
  • Urogenital disease
  • Prostatic disease
  • Hormone antagonists
  • Hormones, hormone substitutes
  • FT-7051
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Diagnosis of progressive castration-resistant prostate cancer (mCRPC)
  • Previously failed at least one potent anti-androgen therapy
  • Castrate levels of serum testosterone
  • performance status 0-2
  • Adequate bone marrow function
  • Adequate kidney, heart and liver function

Exclusion criteria

Exclusion Criteria:

  • Prior solid organ transplant
  • Prior treatment with small molecules including chemotherapy, antibody, or other experimental anticancer therapeutic within 4 weeks of first dose of study treatment
  • Prior radiation therapy within 4 weeks prior to initiation of study treatment (including radiofrequency ablation)
  • Prior androgen antagonist therapy (enzalutamide, apalutamide, abiraterone acetate, or darolutamide) within 2 weeks
  • Prior radium-223 therapy within 6 weeks
  • Symptomatic, untreated or actively progressing central nervous system (CNS)
  • Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes, active or uncontrolled infection requiring systemic therapy) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgement, increase the risk to the patient associated with participation in the study
  • Concomitant medications that cause Torsades de Pointes that have not reached steady state before first dose of the study drug
  • Concomitant medications that are strong inhibitors or inducers of or an inhibitor of P-gp
  • History of infection with (HIV)
  • Active infection with , or virus
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Dose escalation study of FT-7051

    Drug: FT-7051

Interventions

  • DrugFT-7051

    Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable. Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level.

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities (DLTs)

    Time frame: Within first 4 weeks of treatment

  2. Serious adverse events (SAEs) and clinically relevant adverse events (AEs)

    Time frame: The treatment duration, predicted average 26 weeks

  3. Incidence of clinical laboratory abnormalities as assessed by CTCAE v5.0

    Time frame: The treatment duration, predicted average 26 weeks

Secondary outcomes

  1. Prostate-specific antigen (PSA): Percent Change from Baseline

    Time frame: 12 weeks

  2. Prostate-specific antigen (PSA): Maximum Decrease from Baseline

    Time frame: The treatment duration, predicted average 26 weeks

  3. Prostate-specific antigen (PSA): Time to Progression

    Time frame: The treatment duration, predicted average 26 weeks

  4. Time to radiographic progression (rTTP)

    Time frame: The treatment duration, predicted average 26 weeks

  5. Overall response rate: radiographic response rate

    Time frame: The treatment duration, predicted average 26 weeks

  6. Complete response rate

    Time frame: The treatment duration, predicted average 26 weeks

  7. Area under the plasma concentration versus time curve (AUC)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  8. Peak Plasma Concentration (Cmax)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  9. Time of peak plasma concentration (Tmax)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  10. Terminal elimination half-life (T 1/2)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  11. Apparent plasma clearance (CL/F)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  12. Apparent volume of distribution (Vd/F)

    Time frame: Blood samples for PK analysis collected at multiple visits during the first 90 days of treatment

  13. Model-based estimate of change from baseline QT interval corrected using Fridericia's correction formula (QTcF) and 90% confidence interval at the estimated Cmax

    Time frame: Electrocardiogram collected at multiple timepoints during the first 45 days of treatment

07

Study locations

8 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • University of Colorado Health
    Aurora, Colorado 80045, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • University of Maryland, Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Icahn School of Medicine at Mt. Sinai
    New York, New York 10029, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Nov 2022, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Oct 5, 2020
StartActual
Dec 30, 2020
Primary completionActual
Nov 8, 2022
CompletionActual
Nov 15, 2022
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04575766
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Dec 30, 2020
Primary completion
Nov 8, 2022
Completion
Nov 15, 2022
Last update
Aug 9, 2023

Study contacts

Emma Barrett, MD
study director · Novo Nordisk A/S

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion